Shots:

• Exelixis has exercised its exclusive option under the companies’ July 2019 agreement to in-license XL114 (formerly AUR104)- following the US FDA’s IND acceptance for P-I study in NHL
• Exelixis has assumed responsibility for the future clinical development- commercialization and global manufacturing of XL114. By exercising the option for XL114- Aurigene received $10M as option exercise payment
• Exelixis previously exercised its option to in-license XL102 from Aurigene in Dec 2020 and initiated a P-I trial of XL102 as a single agent and in combination with other anti-cancer agents in patients with advanced or metastatic solid tumors in Jan 2021

Ref: Businesswire | Image: Twitter